Sugi Predict

Sugi Predict / Compounds / SCHEMBL1319964

SCHEMBL1319964

SCHEMBL1319964

CC(=O)CC(=O)OC1CCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NAAA Q02083 2/20 0.47
▸ MGAM O43451 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ SI P14410 1/20 0.46
▸ MGAM2 Q2M2H8 1/20 0.46
▸ EPHX1 P07099 2/20 0.46
▸ HTT P42858 2/20 0.44
▸ CYP2C19 P33261 1/20 0.43
▸ CYP19A1 P11511 3/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ APOBEC3A P31941 1/20 0.36
▸ APOBEC3G Q9HC16 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ TPSAB1 Q15661 3/20 0.35
▸ PRSS1 P07477 1/20 0.35
▸ TPSD1 Q9BZJ3 2/20 0.33
▸ TPSG1 Q9NRR2 2/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ TSHR P16473 2/20 0.33
▸ ALOX15 P16050 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2005549 0.96 NAAA (0.52) NAAAMGAMGAASIMGAM2
SCHEMBL7636739 0.94 EPHX1 (0.53) NAAAMGAMGAASIMGAM2
SCHEMBL7740543 0.91 GAA (0.50) NAAAMGAMGAASIMGAM2
SCHEMBL11293843 0.91 GAA (0.50) NAAAMGAMGAASIMGAM2
SCHEMBL6058407 0.86 NAAA (0.48) NAAAEPHX1HTTCYP2C19CYP19A1
SCHEMBL7427174 0.82 MGAM (0.41) NAAAMGAMGAASIMGAM2
SCHEMBL240891 0.81 NAAA (0.53) NAAAEPHX1HTTCYP2C19CYP19A1
SCHEMBL20954557 0.80 MGAM (0.40) NAAAMGAMGAASIMGAM2
SCHEMBL20954287 0.80 ALDH1A1 (0.50) MGAMGAASIMGAM2SMN1; SMN2
SCHEMBL6939177 0.80 GAA (0.40) NAAAMGAMGAASIMGAM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111491935-B Novel analogs as modulators of androgen and glucocorticoid receptors 昂科斯特拉公司 2023-08-22 — — CN disclosed
EP-3707143-B9 NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS ONCOSTELLAE S L (ES) 2023-04-12 — — EP disclosed
EP-3707143-B1 NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS ONCOSTELLAE S L (ES) 2022-12-28 — — EP disclosed
US-11453660-B2 Androgen receptor and glucocorticoid receptor modulators ONCOSTELLAE, S.L. 2022-09-27 — — US disclosed
US-20200325123-A1 NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS ONCOSTELLAE, S.L. (ES) 2020-10-15 — — US disclosed
EP-3707143-A1 NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS Oncostellae, S.L. (ES) 2020-09-16 — — EP disclosed
EP-3480201-A1 NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS Oncostellae, S.L. (ES) 2019-05-08 — — EP disclosed
EP-2789613-B1 1, 4-DIHYDRO-NAPHTHYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION AND USE THEREOF YANTAI YENEPHARMA CO LTD (CN) 2019-02-13 — — EP disclosed
US-9284330-B2 1,4-dihydro-naphthyridine derivative and pharmaceutical composition and use thereof JIANGSU SIMOVAY PHARMACEUTICAL CO., LTD. (CN) 2016-03-15 — — US disclosed
US-9284330-B2 1,4-dihydro-naphthyridine derivative and pharmaceutical composition and use thereof JIANGSU SIMOVAY PHARMACEUTICAL CO., LTD. (CN) 2016-03-15 — — US disclosed
EP-1926727-B1 4-CHROMENONYL-1,4-DIHYDROPYRIDINECARBONITRILES AND THE USE THEREOF Bayer Pharma AG (DE) 2011-09-14 — — EP disclosed
EP-1926727-B1 4-CHROMENONYL-1,4-DIHYDROPYRIDINECARBONITRILES AND THE USE THEREOF Bayer Pharma AG (DE) 2011-09-14 — — EP disclosed
US-20090214675-A1 4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof BAYER HEALTHCARE AG (DE) 2009-08-27 — — US disclosed
US-20090214675-A1 4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof BAYER HEALTHCARE AG (DE) 2009-08-27 — — US disclosed
US-20090214675-A1 4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof BAYER HEALTHCARE AG (DE) 2009-08-27 — — US disclosed
EP-1926727-A1 4-CHROMENONYL-1,4-DIHYDROPYRIDINECARBONITRILES AND THE USE THEREOF Bayer HealthCare AG (DE) 2008-06-04 — — EP disclosed
WO-2007009670-A1 4-CHROMENONYL-1,4-DIHYDROPYRIDINECARBONITRILES AND THE USE THEREOF BAYER HEALTHCARE AG (DE) 2007-01-25 — — WO disclosed
WO-2007009670-A1 4-CHROMENONYL-1,4-DIHYDROPYRIDINECARBONITRILES AND THE USE THEREOF BAYER HEALTHCARE AG (DE) 2007-01-25 — — WO disclosed
US-4686217-A HYPOTENSIVE AGENTS, CARDIOVASCULAR DISORDERS FISONS PLC (GB) 1987-08-11 — — US disclosed
EP-0125803-A2 Pharmaceutically active dihydropyridines FISONS plc (GB) 1984-11-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090214675-A1 4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof RYR1, TNNI3, RYR2 NAAA 3913/4885MGAM 3178/4885GAA 1674/4885
US-20200325123-A1 NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS NR5A1, AR, NR3C1 NAAA 4625/4885MGAM 2651/4885GAA 3786/4885
US-11453660-B2 Androgen receptor and glucocorticoid receptor modulators AR, NR5A1, NR3C1 NAAA 4708/4885MGAM 2530/4885GAA 3692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.